

Day One: Monday, October 24, 2016

7 to 8:30 am	Breakfast	
8:30 to 9 am	Welcome	
	Connected ribbons	Laura Rossano, FOP Community Advocate
	Opening remarks	Betsy Bogard, International FOP Association
9 to 10:30 am	FOP Talks 1: Updates on Current FOP Clinical Research (<i>12-minute talks, except as noted</i>)	
	Palovarotene Phase 2 Trial: Top line results (<i>20 minutes</i>)	Fred Kaplan, M.D., University of Pennsylvania and Donna Grogan, M.D., Clementia Pharmaceuticals
	Expanding our knowledge of FOP: The Clementia FOP Natural History Study	Ed Hsiao, M.D., Ph.D., University of California, San Francisco
	FOP Connection Registry: A cornerstone in FOP research	Neal Mantick, International FOP Association
	Questions & answers	
	Facilitated discussion: Gaps and next steps	Chris Scott, M.D., Red Cross War Memorial Children's Hospital, Cape Town, South Africa
10:30 to 11 am	Coffee Break	
11 am to 12:45 pm	FOP Talks 2: Informing Trial Design: Learnings from Observational and Preclinical Data (<i>12-minute talks</i>)	
	Progress toward biomarkers of FOP	Robert Pignolo, M.D., Ph.D., Mayo Clinic
	Can 18F-NaF PET/CT scan quantitate development of HO lesions in FOP?	Marelise Eekhoff, M.D., Ph.D. and Coen Netelenbos, M.D., Ph.D., VU University Medical Center, Amsterdam, Netherlands
	Visualization of heterotopic bone formation in FOP mice	Jeff Hunter, Alexion Pharmaceuticals
	New insights from a genetically accurate and physiologically relevant mouse model of FOP	Aris Economides, Ph.D., Regeneron Pharmaceuticals
	FOP lesion development: Opportunities for intervention	Eileen Shore, Ph.D., University of Pennsylvania
	Questions & answers	
	Facilitated discussion: Gaps and next steps	Chris Scott, M.D., Red Cross War Memorial Children's Hospital, Cape Town, South Africa
12:45 to 1:45 pm	Lunch	
1:45 to 4 pm	FOP Talks 3: ACVR1/ALK2 Pathway Inhibition in FOP (<i>12-minute talks</i>)	
	Clinical translation of novel discoveries of activin A in FOP mice	Xiaobing Qian, M.D., Ph.D., Regeneron Pharmaceuticals
	Repurposing saracatinib for FOP treatment	Alex Bullock, Ph.D., University of Oxford, UK
	Small molecule Alk inhibitors to reduce heterotopic ossification in the ALK2 ^{Q207D} mouse model: March toward the clinic	Dan Perrien, Ph.D., Vanderbilt University Medical Center
	Discovery of ALK2 inhibitors via nanocyclix chemistry and their use in FOP	Josselin Caradec, Ph.D., Oncodesign, Dijon, France
	Characterization of highly selective ALK2 inhibitors for the treatment of FOP	Andrew Garner, Ph.D., Blueprint Medicines
	A tool desired for FOP	Takenobu Katagiri, Ph.D., Saitama Medical University, Saitama, Japan
	Questions & answers	
	Facilitated discussion: Gaps and next steps	Jay Groppe, Ph.D., Texas A&M University College of Dentistry
4 to 4:30 pm	Coffee Break	
4:30 to 5 pm	Enabling Access to Therapies	
	FOP Patient Narrative Project	Stéphanie Hoffmann, Clementia Pharmaceuticals
	Questions & answers	
5 to 6 pm	FOP Patient Panel I: Perspectives on FOP Drug Development	
	Panelists: Monica Anderson, Erin Danzer & Lori Danzer, Shannon Halford & Raina Halford, Brian Harwell, Tim Hazlett & Debbie Hazlett, Laura Rossano	Moderator: Michelle Davis, International FOP Association
	Questions & answers	
7 to 9:30 pm	Drug Development Forum Dinner	

Day Two: Tuesday, October 25, 2016

7 to 8:30 am	Breakfast	
8:30 to 8:45 am	Welcome Back	
	Opening remarks	Betsy Bogard, International FOP Association
8:45 to 10:45am	FOP Talks 4: New Therapeutic Approaches, Part I (12-minute talks)	
	Cellular response to hypoxia fuels FOP flare-ups	Fred Kaplan, M.D., University of Pennsylvania
	The immunological contribution to heterotopic ossification in FOP	Michael Convente, B.A., University of Pennsylvania
	Targeting hypoxic signaling to prevent traumatic and genetic heterotopic ossification	Benjamin Levi, M.D., University of Michigan
	Mast cell inhibition as a therapeutic approach in FOP	Robert Pignolo, M.D., Ph.D., Mayo Clinic
	Two tissue-resident progenitor populations regulate distinct phenotypes of FOP	Paul Yu, M.D., Ph.D., Brigham and Women's Hospital and Harvard Medical School
	Cells and signals that regulate heterotopic ossification in FOP	David Goldhamer, Ph.D., University of Connecticut Stem Cell Institute
	Questions & answers	
	Facilitated discussion: Gaps and next steps	Roberto Ravazzolo, Ph.D., University of Genova, Italy
10:45 to 11:15 am	Coffee Break	
11:15 am to 1 pm	FOP Talks 5: New Therapeutic Approaches, Part II (12-minute talks)	
	Application of disease-specific iPS cells for FOP research	Junya Toguchida, M.D., Ph.D., Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan
	The use of electronic health record-linked DNA database in drug development for FOP	Charles Hong, M.D., Ph.D., Vanderbilt University Medical Center
	Involvement of TGF-beta Activating Kinase 1 (TAK1) during heterotopic ossification	Yuji Mishina, M.D., University of Michigan School of Dentistry
	Act 2 for Act A: The human story	Haitao Wang, Ph.D., University of Pennsylvania
	The impact of voluntary exercise on joint ossification in the ACVR1[R206H] knock-in mouse model of FOP	Paul Yu, M.D., Ph.D., Brigham and Women's Hospital and Harvard Medical School
	Questions & answers	
	Facilitated discussion: Gaps and next steps	Roberto Ravazzolo, Ph.D., University of Genova, Italy
1 to 2 pm	Lunch	
2 to 2:15 pm	IFOPA Talk	
	IFOPA: The voice of the community	Michelle Davis, International FOP Association
2:15 to 3:15 pm	FOP Patient Panel II: A Broad View of FOP	
	Panelists: Andrew Davis, Sophia Forshtay & Connie Green & David Forshtay, Jaxon Hamilton & Lara Theoret, Justin Henke & Wendy Henke, Sarah Steele (via phone)	Moderator: Michelle Davis, International FOP Association
	Questions & answers	
3:15 to 4 pm	Closing	
	Meeting outcomes and closing remarks	Betsy Bogard, International FOP Association
	How did we get here?	Aarti Madan, FOP Community Advocate
	Adjourn	